Viewing Study NCT04951635


Ignite Creation Date: 2025-12-24 @ 10:13 PM
Ignite Modification Date: 2026-05-19 @ 7:45 AM
Study NCT ID: NCT04951635
Status: RECRUITING
Last Update Posted: 2022-06-16
First Post: 2021-06-30
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Phase III, stage III NSCLC, unresectable NSCLC, Almonertinib, Maintenance Therapy, … View